13 results about "Nimodipine" patented technology

The invention provides a composition for treating nerve headache and a preparation method thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: carrying out steam explosion treatment on traditional Chinese medicine powder, adding the traditional Chinese medicine powder into saline water, decocting, filtering, standing filtrate to separate out a hydrochloric acid extract, adding filter residues into ethanol, adsorbing by a magnetic adsorbent, separating by a magnet, eluting, desorbing, recovering an eluent to obtain an alcohol extract, mixing and grinding the alcohol extract, the hydrochloric acid extract and flunarizine hydrochloride / nimodipine eutectic, and filling capsules with the alcohol extract and the flunarizine hydrochloride / nimodipine eutectic. The composition for treating the nerve headache is prepared. The traditional Chinese medicine composition treats neuropathic migraine through a method of combining traditional Chinese medicine and western medicine, treats both symptoms and root causes, and is good in effect and quick and lasting in effect.

The invention relates to the field of traditional Chinese medicines, in particular to a preparation method of an Anqi flat-pressing capsule which comprises the following components in parts by weight: 6-7 parts of astragalus membranaceus, 6-7 parts of codonopsis pilosula, 4g of salvia miltiorrhiza, 5-6 parts of cortex moutan, 5-6 parts of malt, 5-6 parts of hawthorn, 3-4 parts of scutellaria baicalensis, 3-4 parts of radix bupleuri, 2.5 g of diazepam, 1-2 parts of nimodipine and 2-3 parts of radix isatidis. The capsule has the effects of nourishing heart, stabilizing mind, promoting blood circulation to remove blood stasis, soothing liver-qi stagnation, dredging and regulating internal organs, regulating qi activity, reducing heart pressure, maintaining normal functions of the heart, enabling qi and blood to be smooth and smooth, coordinating functions of the internal organs, reducing resistance and reducing blood pressure, so that the heart is protected against mind, and the main mind is relieved if the main mind is relieved. The capsule has the advantages of normal heart function, reduced pressure, relatively stable blood pressure, smooth qi and blood, healthy body and no occurrence of diseases, can be used for treating various hypertension and intractable hypertension diseases, and has no side effect.

The present application relates to the technical field of medicine, in particular to a safe and stable nimodipine for injection and a preparation method thereof, and provides a nimodipine cyclodextrin freeze-dried powder injection containing sulfobutyl ether-beta-cyclodextrin, which can significantly improve the solubility, drug safety and dilution stability of nimodipine, increase the compliance of patients and the convenience of clinical use. Compared with the commercially available nimodipine injection, the safety and dilution stability of the present application are significantly improved, and the present application has obvious advantages.

The application provides semi total flavonoids of Liquidambar, which is obtained by using stems of Liquidambar cathayensis Hung T.Chang as raw materials and adopting ultrasonic-assisted low eutectic solvent extraction, wherein the yield of the total flavonoids is 71.95%±6.49%. The application also provides a preparation method and application of the semi total flavonoids of Liquidambar. The semi total flavonoids of Liquidambar have significant antioxidant activity, can be used for nerve protection, can be used for treating cerebral ischemia or anti-ischemic stroke, can improve cerebral ischemic nerve function injury, can reduce cerebral infarction volume, can reduce neuron damage degree, can reduce activation of astrocytes, can reduce expression level of apoptotic proteins, can protect neurons and synapses, and can protect vascular endothelial cells. The drug efficacy is clear and controllable, is equivalent to that of positive drug nimodipine, can reach significant drug efficacy at a low dose, is safer in clinical use, and provides a new selection for clinic.

The application relates to application of a dihydropyridine compound or a salt thereof in preparation of a medicine for preventing and / or treating HPV infection, and belongs to the technical field of medicines and pharmaceutical preparations. The application provides application of the dihydropyridine compound or the salt thereof in preparation of the medicine for preventing and / or treating HPV infection, wherein the dihydropyridine compound is selected from one or more of nifedipine, amlodipine, lercanidipine, nimodipine, nitrendipine, nisoldipine, felodipine, benidipine, lacidipine and azelnidipine. The application scheme first reports the application of the dihydropyridine compound or the salt thereof in prevention and / or treatment of HPV, and in-vitro cell experiments are carried out through azelnidipine in the dihydropyridine compound, and further, the inhibiting effect of the dihydropyridine compound on HPV virus is verified through medicine administration of a mouse intradermal virus inoculation model and medicine administration of a mouse vaginal virus inoculation model.

Disclosed are a nimodipine injection composition and preparation method therefor. The nimodipine injection composition includes the following components in parts by mass concentration: 0.02-0.23% of nimodipine, 2-30% of oil for injection, 0.8-3% of emulsifier, 0-0.1% of complexing agent, 0-0.3% of stabilizer, 1-3% of osmotic pressure adjusting agent. The composition does not contain solubilizers such as ethanol, auxiliary emulsifiers such as tween-80, and cosolvents such as benzyl alcohol.

The invention discloses application of nimodipine in preparation of a medicine for treating acute liver injury by inducing UGT1A1, and belongs to the technical field of regulation and control of metabolic enzymes of medicines. According to the application of nimodipine in preparation of the medicine for treating acute liver injury by inducing UGT1A1, nimodipine can induce expression of UGT1A1, and the mRNA and protein expression level of enzyme can be remarkably up-regulated. The invention can be used for regulating drug metabolism, hyperbilirubinemia and other diseases caused by insufficient expression of UGT1A1. The application range of nimodipine is expanded, and a new strategy is provided for individualized drug therapy.

The present invention relates to the technical field of pharmaceutics, and in particular, to a safe and stable nimodipine formulation for injection and a method for preparing same. The present invention provides a lyophilized nimodipine-cyclodextrin powder for injection, comprising sulfobutylether-β-cyclodextrin, which can significantly improve the solubility, safety, and dilution stability of nimodipine, and increase patient compliance and the convenience of clinical use. Compared with a commercially available nimodipine injection NIMOTOP, the present invention has significant advantages in safety and dilution stability.

A method of providing an IV nimodipine infusion regimen using a solubilized nimodipine solution suitable for IV administration is disclosed. The IV nimodipine infusion regimen provides a constant infusion rate over the (entire) 24-hour period supplemented with higher infusions of nimodipine at set intervals to duplicate the 24-hour AUC and Cmax of an oral nimodipine dose.

A nimodipine composition, comprising nimodipine or a pharmaceutically acceptable salt of nimodipine, cyclodextrin, stabilizer 1, stabilizer 2, and no more than 1% (w / w) organic solvent in the combination. A preparation method for nimodipine for injection, wherein the nimodipine for injection is prepared from the composition and a solvent, and the solvent is selected from ethanol and / or water. The mass ratio of sulfobutyl ether-β-cyclodextrin to nimodipine in the nimodipine composition for injection of the present disclosure is smaller, which can be expected to reduce the safety hazards caused by sulfobutyl ether-β-cyclodextrin. The ethanol proportion of the nimodipine composition for injection of the present disclosure is significantly reduced compared to Nimotop, avoiding the toxicity problems caused by the use of large amounts of organic solvents and improving patient compliance.

Liquid compositions comprising nimodipine having improved nimodipine concentrations are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the liquid compositions of the present invention are also detailed herein.

The application discloses a nimodipine crystal form and an inducing method thereof, and has the technical scheme that a trace amount of an organic solvent is added into nimodipine, grinding beads with different diameters are put into the nimodipine, the crystal form is induced and changed by grinding, and a new crystal form is obtained after drying; the method controls the material and size of the grinding beads, adjusts the kinetic process of the crystal form change, and remarkably improves the purity and stability of the target crystal form; the amount of the organic solvent used is extremely low, the green pharmaceutical principle is met, the process is simple, the repeatability is good, and the method is suitable for industrial production.

Provided are a moist-heat sterilized nimodipine composition free of ethanol and phospholipid and a method for preparing the same. The composition comprises (1) nimodipine; (2) a non-phospholipid surfactant selected from polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyoxyl 15 hydroxystearate, D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS), polysorbates, glyceryl monocaprylocaprate, or any mixture of two or more thereof; and (3) a co-solvent, which is propylene glycol.